Metabiomics Press Releases
Origin Sciences and Metabiomics Announce Exclusive Distribution Agreement of OriCol™ Microbiome Sampling Kits in the U.S.
PRESS RELEASE Cambridge, UK and Aurora, CO December 16, 2015 Metabiomics Corp. announced it has secured a distribution agreement with Origin Sciences pursuant to which it will develop, test, and commercialize the novel OriCol™ gastrointestinal sampling technology for...
San Diego, CA September 10, 2015 Metabiomics is pleased to be attending the 3rd annual Global Engage Microbiome R&D and Business Collaboraton Forum. Greg Kuehn, President and COO will be giving a talk on Day 2 (sept 11) covering the...
Metabiomics expands management team and advisory board to include Dr. Louis Korman, Dr. Robert Hardi, Dr. Jeffrey Baybick and Dr. Paul DeRidder. The new team members have extensive clinical research, healthcare, gastroenterology, pathology and international business development experience.
Metabiomics is pleased to announce the addition of a new key member to our management team. Dr. David Hanzel has joined Metabiomics as our President and Chief Operating Officer.
Metabiomics to Present Colorectal Cancer Screening Test at Upcoming Investor Conference, OneMedForumNY 2013
Metabiomics, an early stage microbiome diagnostics company, will be presenting an investment opportunity next week at OneMedForumNY in New York.
Metabiomics and Chinese Health Testing Leader Kindstar Global form Partnership to Develop a Microbiome and Next-Generation Sequencing-Based Screening Test for Colorectal Cancer
Metabiomics and Kindstar Global, a leading specialty clinical testing laboratory in China, have signed a licensing and distribution deal for the development of the world’s first microbiome-based screening test for colon polyps and colorectal cancer.
Metabiomics Selected to Present a Next-Generation Sequencing Cancer Diagnostics Strategy at Two Upcoming Investor Conferences
Metabiomics, an early stage molecular diagnostics firm, will visit Denver, Colorado and Orange County, California next week to present a business plan and growth strategy for commercializing a non-invasive screening test for colorectal cancer.
New Metabiomics Screening Test for Early Detection and Prevention of Colorectal Cancer Poised to Reduce Health Care Costs and Save Lives
Metabiomics Selected to Present Molecular Diagnostic Innovations and Growth Strategy at Annual Mid-Atlantic BIO Conference Potomac Falls, Virginia (September 17, 2012) Metabiomics, a Northern-VA-based molecular diagnostics firm, was selected by the Mid-Atlantic Bio...
Metabiomics® announced today that it has been awarded patent number EP 1815016 B1 titled “Compositions and Methods for Diagnosing Colon Disorders” by the European Patent Office (EPO).